ES2230480T3 - Tripeptidos y derivados de tripeptidos para el tratamiento de enfermedades potlesionales del sistema nervioso. - Google Patents

Tripeptidos y derivados de tripeptidos para el tratamiento de enfermedades potlesionales del sistema nervioso.

Info

Publication number
ES2230480T3
ES2230480T3 ES02719767T ES02719767T ES2230480T3 ES 2230480 T3 ES2230480 T3 ES 2230480T3 ES 02719767 T ES02719767 T ES 02719767T ES 02719767 T ES02719767 T ES 02719767T ES 2230480 T3 ES2230480 T3 ES 2230480T3
Authority
ES
Spain
Prior art keywords
sub
ile
alkyl
tripeptides
phe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02719767T
Other languages
English (en)
Spanish (es)
Inventor
Jean Rapin
Hans Klaus Witzmann
Jean-Marie Grumel
Jacques Gonella
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NeuroTell AG
Original Assignee
NeuroTell AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NeuroTell AG filed Critical NeuroTell AG
Application granted granted Critical
Publication of ES2230480T3 publication Critical patent/ES2230480T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES02719767T 2001-02-05 2002-02-05 Tripeptidos y derivados de tripeptidos para el tratamiento de enfermedades potlesionales del sistema nervioso. Expired - Lifetime ES2230480T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10105038A DE10105038B4 (de) 2001-02-05 2001-02-05 Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems
DE10105038 2001-02-05

Publications (1)

Publication Number Publication Date
ES2230480T3 true ES2230480T3 (es) 2005-05-01

Family

ID=7672831

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02719767T Expired - Lifetime ES2230480T3 (es) 2001-02-05 2002-02-05 Tripeptidos y derivados de tripeptidos para el tratamiento de enfermedades potlesionales del sistema nervioso.

Country Status (8)

Country Link
US (1) US7122524B2 (enExample)
EP (1) EP1363656B1 (enExample)
JP (1) JP4183507B2 (enExample)
AT (1) ATE285244T1 (enExample)
DE (2) DE10105038B4 (enExample)
ES (1) ES2230480T3 (enExample)
PT (1) PT1363656E (enExample)
WO (1) WO2002062373A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10105038B4 (de) 2001-02-05 2005-07-07 Neurotell Ag Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems
DE10105041A1 (de) 2001-02-05 2002-08-14 Tell Pharm Ag Hergiswil Tripeptide und Tripeptid-Derivate für die Behandlung neurodegenerativer Krankheiten
DE10105040A1 (de) 2001-02-05 2002-08-14 Tell Pharm Ag Hergiswil Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems
JP2011201923A (ja) * 2005-07-01 2011-10-13 Snow Brand Milk Products Co Ltd ジペプチジルペプチダーゼｉｖ阻害剤
CN106317177A (zh) * 2015-06-23 2017-01-11 首都医科大学 Gly-Phe-Pro,其合成,活性和应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1323301C (en) * 1987-06-05 1993-10-19 Alan I. Faden Thyrotropin-releasing hormone analogs in cns injury
FR2622581B1 (fr) * 1987-11-03 1990-02-16 Inorgan Sa Rech Develop Pharm Nouveaux derives de l-proline, leur preparation et leurs applications biologiques
EP0445606B1 (en) * 1990-02-27 1997-01-22 The Agency of Industrial Science and Technology Novel oligopeptides, pharmaceutical composition and food containing the same, and use of oligopeptides
DE4007869A1 (de) 1990-03-13 1991-09-19 Merck Patent Gmbh Aminosaeurederivate
JPH045240A (ja) 1990-04-20 1992-01-09 Taisho Pharmaceut Co Ltd 抗痴呆剤
US5091391A (en) * 1990-08-16 1992-02-25 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of resisting neurodegenerative disorders
JPH06504061A (ja) 1990-12-28 1994-05-12 コーテックス　ファーマシューティカルズ　インコーポレイテッド 神経変性の治療および予防におけるカルパイン阻害剤の使用
WO1992013549A1 (en) * 1991-02-07 1992-08-20 Research Corporation Technologies, Inc. Inhibition of cell proliferation by hydrophobic peptides
US6235929B1 (en) 1991-12-27 2001-05-22 Georgia Tech Research Corporation Tripeptide α-ketoamides
ZA95260B (en) * 1994-01-13 1995-09-28 Univ Columbia Synthetic receptors libraries and uses thereof
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5834029A (en) 1994-07-20 1998-11-10 Cytotherapeutics, Inc. Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment
JPH0940577A (ja) * 1995-05-24 1997-02-10 Mitsui Toatsu Chem Inc トリペプチド、ジペプチドを含有する医薬組成物
EP0840614A1 (en) 1995-06-13 1998-05-13 Sanofi Winthrop, Inc. Calpain inhibitors for the treatment of neurodegenerative diseases
JPH09169797A (ja) * 1995-12-22 1997-06-30 Mitsui Toatsu Chem Inc プロテアーゼアクティベーター活性を有するペプチド
US5840838A (en) * 1996-02-29 1998-11-24 University Of Kentucky Research Foundation Process for enhancing the activity of amyloid β peptides
JP2001501930A (ja) * 1996-10-04 2001-02-13 オークランド ユニサーヴィスィズ リミテッド 神経酵素の調節
JP4727770B2 (ja) 1997-09-26 2011-07-20 カルピス株式会社 尿中カテコールアミン低下、尿中ノルアドレナリン低下、尿中ドーパミン低下及びＦｉｓｃｈｅｒ比低下の少なくとも１つの軽減剤
US6080848A (en) * 1998-05-01 2000-06-27 Incyte Pharmaceuticals, Inc. Human brain associated protein
US6379691B1 (en) * 1998-09-29 2002-04-30 Medtronic/Ave, Inc. Uses for medical devices having a lubricious, nitric oxide-releasing coating
AU1574701A (en) * 1999-10-22 2001-04-30 Wrair Walter Reed Army Institute Of Research A pharmaceutical composition containing pglu-glu-pro-nh2 and method for treating diseases and injuries to the brain, spinal cord and retina using same
JP4633876B2 (ja) 1999-11-11 2011-02-16 カルピス株式会社 トリペプチドの製造方法
WO2001068114A1 (en) 2000-03-10 2001-09-20 Monsanto Company Novel peptides with anti-hypertensive activity
DE10105041A1 (de) 2001-02-05 2002-08-14 Tell Pharm Ag Hergiswil Tripeptide und Tripeptid-Derivate für die Behandlung neurodegenerativer Krankheiten
DE10105038B4 (de) 2001-02-05 2005-07-07 Neurotell Ag Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems
US6846641B2 (en) * 2002-04-23 2005-01-25 Agy Therapeutics, Inc. In vitro ischemia model

Also Published As

Publication number Publication date
JP2004526702A (ja) 2004-09-02
DE10105038A1 (de) 2002-08-14
US7122524B2 (en) 2006-10-17
US20050080016A1 (en) 2005-04-14
DE60202356T2 (de) 2005-12-08
DE60202356D1 (de) 2005-01-27
WO2002062373A3 (en) 2002-11-14
PT1363656E (pt) 2005-03-31
JP4183507B2 (ja) 2008-11-19
EP1363656B1 (en) 2004-12-22
ATE285244T1 (de) 2005-01-15
WO2002062373A2 (en) 2002-08-15
DE10105038B4 (de) 2005-07-07
EP1363656A2 (en) 2003-11-26

Similar Documents

Publication Publication Date Title
US7041784B2 (en) Apoptotic compounds
CA2067505A1 (en) Methods and compositions for healing bone
CN101541743A (zh) 多肽及相关化合物的透皮给药系统
ES2952519T3 (es) Polipéptidos cíclicos, su procedimiento de obtención y su aplicación en terapéutica
CN109929001A (zh) 葡萄糖胺衍生物、其组合物及其医药用途
ES2230480T3 (es) Tripeptidos y derivados de tripeptidos para el tratamiento de enfermedades potlesionales del sistema nervioso.
RU2559880C1 (ru) Замещенный бисдипептид с нейропротективным и антидепрессивным эффектом
US7129213B2 (en) Tripeptides and tripeptide derivatives for the treatment of neurodegenerative diseases
KR20120134100A (ko) 벡터적 이온 채널의 조절을 위한 유기화합물
RU2242241C1 (ru) Тетрапептид, регулирующий уровень глюкозы при сахарном диабете, фармакологическое средство на его основе и способ его применения
CN112830884B (zh) 一种丹参素衍生物及其制备方法及其医药用途
ES2342874B2 (es) Peptidos ciclicos inhibidores del crecimiento celular.
RU2286169C1 (ru) Семейство пептидов, обладающее анальгетической активностью
ES2250617T3 (es) Derivados de tripeptidos para el tratamiento de enfermedades postlesion del sistema nervioso.
Sidorova et al. Synthesis of the antagonist of the GalR2 galanin receptor and studies of its biological activity in ischemia and reperfusion of the rat heart in vivo
US8772248B2 (en) Drug delivery system
BR112019028134A2 (pt) peptídeo pró-fármaco com propriedades farmacêuticas
RU2517209C2 (ru) Средство, обладающее ноотропным воздействием на организм
CN120665156A (zh) N-甲基化修饰环肽及其应用
WO2020067923A1 (ru) Нонапептид, предотвращающий повышение гиперпроницаемости сосудистого эндотелия
CN105440104A (zh) 多肽及相关化合物的透皮给药系统
JPH07242563A (ja) ガン転移抑制剤
HU196226B (en) Process for producing new tripeptide derivatives of antiamnesic activity and pharmaceutical compositions containing them as active components